Grifols SA GRFS
Grifols SA (Nasdaq: GRFS) is a hematology drug developer. Its lead program, Fibrinogen concentrate (BT524), is in Phase 3 for Congenital fibrinogen deficiency (US BLA approved 2025); acquired fibrinogen deficiency (EU approved, US Phase III to start 2026). Its next catalyst on record is Fibrinogen BT524: US commercial sales start (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Fibrinogen BT524 — US commercial sales start (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Fibrinogen BT524 | Congenital fibrinogen deficiency (US); congenital and acquired deficiency (EU) | biologic-other | Approved |
| Prolastin-C (alpha-1 proteinase inhibitor, IV) - SPARTA | Emphysema due to congenital alpha-1 antitrypsin deficiency | biologic-other | Approved |
| Xembify (subcutaneous immunoglobulin) | Secondary immunodeficiency in CLL, multiple myeloma and NHL | biologic-other | Phase 3 |
| Trimodulin | Severe community-acquired pneumonia (sCAP) | biologic-other | Phase 3 |
| Alpha-1 Proteinase Inhibitor SC 15% | Emphysema due to congenital alpha-1 deficiency (subcutaneous) | biologic-other | Phase 2 |
| Immunoglobulin eye drops (Flebogamma DIF 5%) | Dry eye disease | biologic-other | Phase 2 |
| ABvac40 (Araclon) | Early-stage Alzheimer's disease (active vaccine against A-beta40) | vaccine | Phase 2 |
| GIGA-2339 (GigaGen) | Hepatitis B virus infection | antibody | Phase 1 |
| GIGA-564 (GigaGen) | Advanced solid tumors | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
- Incyte Corp INCY
- Disc Medicine, Inc. IRON
- Agios Pharmaceuticals, Inc. AGIO
- Geron Corporation GERN
- Nuvectis Pharma, Inc. NVCT
- X4 Pharmaceuticals, Inc XFOR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.